Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GCKR | Q14397 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22055123 | 0.79 | HDAC1 (0.55) | MAPTMAPK1HTTNPSR1HDAC1 | |
| SCHEMBL9307239 | 0.75 | MAPK1 (0.43) | MAPTMAPK1HTTNPSR1HDAC1 | |
| SCHEMBL13699526 | 0.73 | SIGMAR1 (0.52) | SMN1; SMN2ALDH1A1POLBSLC18A3 | |
| SCHEMBL15315675 | 0.73 | SIGMAR1 (0.52) | SMN1; SMN2ALDH1A1POLBSLC18A3 | |
| SCHEMBL13134572 | 0.72 | DRD2 (0.54) | MAPTMAPK1 | |
| SCHEMBL28641701 | 0.72 | P2RX7 (0.42) | MAPTMAPK1HTTNPSR1ALDH1A1 | |
| SCHEMBL5530018 | 0.72 | CHRNB2 (0.58) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3011993 | 0.72 | CHRNB2 (0.58) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2293883 | 0.71 | MAPT (0.42) | MAPTMAPK1HTTNPSR1HDAC1 | |
| SCHEMBL28866229 | 0.70 | CHRNB2 (0.56) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MAPT 3800/4885MAPK1 1202/4885HTT 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.